Loading...
•
Jun 30, 2020
Ardelyx Q2 2020 Earnings Report
Reported financial results for the second quarter of 2020 and provided business highlights.
Key Takeaways
Ardelyx reported $1.8 million in revenue for Q2 2020, primarily from collaborative development. The company submitted a New Drug Application to the FDA for tenapanor and maintained a strong balance sheet with $204.8 million in cash, cash equivalents, and short-term investments.
Submitted a New Drug Application to the FDA for tenapanor for hyperphosphatemia.
Released additional positive data from the ongoing NORMALIZE Phase 4 study.
Kyowa Kirin Co., Ltd. (KKC) presented positive data at ERA-EDTA 2020 on tenapanor's ability to reduce pill burden.
Strengthened leadership team with the appointment of a chief financial officer and chief commercial officer.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...